Trials / Not Yet Recruiting
Not Yet RecruitingNCT07523711
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
A Phase 1, Open-label Study to Assess the Effect of Maridebart Cafraglutide (AMG 133) on the Pharmacokinetics of Oral Contraceptives in Postmenopausal Female Participants Living With Overweight or Obesity
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | COC | Administered orally. |
| DRUG | Maridebart Cafraglutide | Administered as SC injection. |
Timeline
- Start date
- 2026-04-09
- Primary completion
- 2026-10-07
- Completion
- 2026-10-07
- First posted
- 2026-04-13
- Last updated
- 2026-04-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07523711. Inclusion in this directory is not an endorsement.